Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

NCT04086472 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Viruses

Interventions

BIOLOGICAL: Clesrovimab
OTHER: Placebo
BIOLOGICAL: RSV-A Memphis 37b

Sponsor

Merck Sharp & Dohme LLC